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for hepatocellular carcinoma (HCC), with locoregional therapies,
is common in most transplant centers. However, for T1 tumors
and expected waiting times to LT <6 months, there is no evidence
that these treatments are beneﬁcial. For T2 tumors and for longer
waiting times, neo-adjuvant treatments are usually performed
with transarterial chemoembolization (TACE), ablation tech-
niques and liver resection in selected cases. The treatment choice
should be based on the BCLC staging system. At present, there is
no evidence of the superiority of ablation/resection vs. TACE, but
some studies showed better results of the former in achieving a
complete response. The response to neo-adjuvant treatments
should be evaluated through mRECIST criteria, but few studies
adopted these criteria and properly analyzed factors affecting
response. The simultaneous evaluation of the impact of neo-
adjuvant therapies on dropout rate, post-LT HCC recurrence and
patient survival is rarely reported. Tumor stage and volume,
alpha-fetoprotein levels, response to treatments and liver func-
tion affect pre-LT outcomes. These same factors, together with
vascular invasion and poor tumor differentiation, are major
determinants of poor post-LT outcomes. Due to the low number
of prospective studies with well-deﬁned entry criteria and the
variability of results, the role of downstaging is still to be deﬁned.
Novel molecular markers seem promising for the estimation of
prognosis and/or response to treatments. With a persistent
scarcity of organ donors, neo-adjuvant treatments can help iden-Journal of Hepatology 20
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Introduction
Hepatocellular carcinoma (HCC) is one of the 5 most common
malignancies worldwide, and its incidence is increasing in
Western countries [1,2]. For patients with HCC and cirrhosis,
liver transplantation (LT) represents the treatment of choice
and provides excellent oncological results and a cure for cir-
rhosis. However, not all patients with HCC and cirrhosis can
undergo transplantation because of the scarcity of liver
donors.
HCC patients on the waiting list (WL) for transplantation can
experience tumor growth beyond the accepted criteria for LT; the
practice of treating HCC patients with hepatic resection or locore-
gional therapies before they are placed on the WL or while they
are awaiting has thus gained favor and is now the standard of
care in most transplant centers [3–6].
Radiofrequency ablation (RFA), percutaneous ethanol injec-
tion (PEI), and transarterial chemoembolization (TACE) have
considerably improved in the last decade, and they can have a
positive impact on tumor growth control [3–7]. Similarly,
the great improvements in diagnostic techniques and surveil-
lance schedules have led to earlier diagnoses and better accu-
racy, and this has resulted in the increased curability of liver
tumors.
Locoregional treatments can be used as neo-adjuvant thera-
pies with two intents in the setting of LT. The ﬁrst one is to pre-
vent the dropout from the WL in patients meeting accepted
criteria of transplantability; in this case, locoregional treatments
are deﬁned as bridging procedures. The second one is to treat
patients initially outside criteria for LT in order to reach T2 stage
HCC, to fulﬁll Milan criteria (MC) [8], University of California
San Francisco criteria (UCSFC) [9], or other criteria, which allows
entry to the WL for LT after an adequate period of follow-up,
to verify the effectiveness of neo-adjuvant treatment. In
this case, locoregional therapies are used as downstaging
procedures.13 vol. 58 j 609–618
Key Points
• Locoregional treatments are widely used in cirrhotic
patients with hepatocellular carcinoma (HCC) listed
for liver transplantation (LT) in order to prevent tumor
progression, even though there is no strong evidence
that neo-adjuvant treatments should be applied if the
expected waiting time for LT is shorter than 6 months
• Neo-adjuvant treatments include transarterial
chemoembolization (TACE), radiofrequency ablation,
ethanol injection and liver resection, which should be
selected according to the Barcelona Clinic Liver Cancer
(BCLC) scoring system
• Other procedures, such as TACE with drug-eluting
beads, transarterial radioembolization, radiotherapy,
microwave ablation, cryoablation and irreversible
electroporation, though promising, are still under
investigation
• The efficacy of neo-adjuvant treatments should be
evaluated by the rate of dropout from the WL and,
methodologically, with a 3-month interval reassessment
of modified Response Evaluation Criteria in Solid
Tumors (mRECIST) and serum alpha-fetoprotein
sampling
• Neo-adjuvant treatments have the 3 main purposes of
controlling HCC progression for expected long waiting
times, identifying patients with different probabilities of
cancer progression and helping in balancing the priority
of HCC and non-HCC candidates for LT
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adjuvant treatment in the management of potential candidates
for LT, the following items will be discussed in the present paper:
(1) Are neo-adjuvant locoregional treatments indicated in
patients considered for LT?
(2) How should response to locoregional treatments be evalu-
ated, and what timing should be adopted for patient mon-
itoring on the WL?
(3) Which types of locoregional treatment are available for
patients considered for LT?
(4) Which is the best neo-adjuvant treatment in this setting?
(5) Which are the patient or tumor characteristics related to
an unsuccessful neo-adjuvant therapy, a higher dropout
rate, and a worse post-LT outcome?
(6) Can the effect of neo-adjuvant treatments be used to bal-
ance priority of HCC and non-HCC candidates?
(7) Are there newmolecular markers for a better estimation of
tumor biological behavior and/or response to treatment?Are neo-adjuvant locoregional treatments indicated in
patients listed for LT?
An international consensus conference was held in 2010 with the
aim of reviewing current practice regarding LT in patients with
HCC and to develop internationally accepted statements and
guidelines [10]. Thirty-seven statements covering all issues of610 Journal of Hepatology 201LT for HCC were produced; among these, 5 statements
were focused on the management of patients on the WL. No
recommendation could be made on bridging therapy in patients
with United Network for Organ Sharing (UNOS) T1 HCC due to
the absence of scientiﬁc evidence. In patients with UNOS T2
HCC and a likely waiting time longer than 6 months, locoregional
therapy may be appropriate, but the low level of evidence for
prognosis led to a weak recommendation. In fact, a cost-effective
analysis based on Markov model and the review of cohort studies,
indicate a beneﬁt for bridging therapies if the waiting time is
expected to be longer than 6 months [11–14]. However, in the
clinical practice and given the often unpredictable waiting time
for LT, there is a widespread attitude to treat most patients in
the WL. In the following sections of this review, we will focus
on the possible beneﬁts derived from the routine adoption of
neo-adjuvant treatments.How should response to locoregional treatments be
evaluated?
Whatever the type of locoregional therapy chosen, the response
to neo-adjuvant treatments should be evaluated with the modi-
ﬁed Response Evaluation Criteria in Solid Tumors (mRECIST)
[15,16]. The RECIST criteria were amended as mRECIST in 2008,
based on the concept that the evaluation of the treatment
response should take into account the induction of intratumoral
necrotic areas in estimating the decrease in tumor load, and not
just a reduction in overall tumor size [17].
Patients can be followed with either contrast-enhanced spiral
computed tomography (CT), preferably with use of multislice
scanners, or contrast-enhanced dynamic magnetic resonance
imaging (MRI). The administration of intravenous contrast is rec-
ommended for CT and MRI, if not medically contraindicated. In
contrast-enhanced studies, it is mandatory to obtain a dual-phase
imaging of the liver [15,16].
According to mRECIST criteria, the following deﬁnitions
should be applied for tumor response to treatment: (A) complete
response: the disappearance of any intratumoral arterial
enhancement in all target lesions; (B) partial response: at least
a 30% decrease in the sum of diameters of viable (contrast
enhancement in the arterial phase) target lesions, taking as the
reference the baseline sum of the diameters of target lesions;
(C) progressive disease: an increase of at least 20% in the sum
of the diameters of viable (enhancing) target lesions, taking as
the reference the smallest sum of the diameters of viable
(enhancing) target lesions recorded since the treatment started;
(D) stable disease: any cases that do not qualify for either partial
response or progressive disease [15,16].
Overall response is a result of the combined assessment of tar-
get lesions, non-target lesions, and new lesions.
Unfortunately, studies focusing on neo-adjuvant treatments
before LT do not report the response to this therapy with uniform
and/or well-deﬁned parameters, and mRECIST, in particular,
have rarely been used so far. Relationships between response to
therapy and dropout from WL should represent the main aim
of any dedicated study on this issue, and the capability of any
proposed neo-adjuvant treatment should be assessed in the view
of dropout due to tumor progression rather than response by
itself.
Conversely, there is general agreement that monitoring of
patients on the WL should be performed with the above reported3 vol. 58 j 609–618
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imaging techniques and the evaluation of serum alpha-fetopro-
tein (AFP) with a 3-month interval after listing [10].Which types of locoregional treatment are available for
patients considered for LT?
Currently, TACE and percutaneous ablation are the treatments
most frequently used in patients listed for LT or included in a
downstaging program. This is also derived from the revised Bar-
celona Clinic Liver Cancer (BCLC) staging system, according to
which local ablation is considered the ﬁrst-line treatment option
for patients at early stages, not suitable for surgical therapies
(BCLC 0-A), while TACE is the ﬁrst-line therapy for patients at
intermediate stages of the disease (unresectable, multifocal dis-
ease conﬁned to the liver in the absence of portal vein thrombosis
and in asymptomatic patients; BCLC B) [18].
Regarding local ablation, RFA is recommended in most
instances as the main ablative therapy in tumors less than 5 cm
due to a signiﬁcantly better control of the disease, while PEI is
recommended in cases where RFA is not technically feasible
(around 10–15%). In selected cases, laparoscopic ablation can be
performed. Other ablative therapies, such as microwave ablation,
cryoablation, and irreversible electroporation are still under
investigation [18].
TACE extends the survival of patients with BCLC stage B from
a median of 16 months (untreated cases) to a median of up to 19–
20 months, according to randomized controlled trials and a meta-
analysis of pooled data [19]. Although not supported by studies
with high levels of evidence, doxorubicin or cisplatin are the best
chemotherapeutical agents to be used with TACE, while the pro-
cedure should be applied 3–4 times per year, since more intense
regimes [i.e., TACE every 2 months] can induce liver failure in an
unacceptable proportion of patients. Superselective TACE is rec-
ommended to minimize the ischemic insult to non-tumoral liver
and to increase the rate of tumor necrosis [7,18].
Alternatives to TACE can be represented by TACE with Drug-
Eluting Beads (TACE-DEB), radioembolization or external radia-
tion. TACE-DEB has shown similar response rates to standard
TACE, with less liver-related toxicity and systemic adverse events
[20,21].
Transarterial radioembolization (TARE) with 131I or 90Y glass
beads has shown a good anti-tumoral effect with an acceptable
safety proﬁle, but at present, it cannot be recommended as stan-
dard therapy, based on the absence of studies with high levels of
evidence comparing TARE with TACE [22–25].
External three-dimensional conformal radiotherapy is under
investigation [26], and at present there is no evidence to support
this therapeutic approach in the management of HCC.
Which is the best neo-adjuvant treatment in patients
considered for LT?
According to the previously mentioned international consensus
conference held in 2010, no recommendation can be made for
preferring any type of locoregional therapy to others, in patients
listed for LT or in those entering a downstaging protocol [10].
This statement is based on the lack of randomized trials on this
topic. Indeed, the potential beneﬁts advocated for local ablation
or TACE are derived from observational studies and cost-effec-
tiveness analyses [10].Journal of Hepatology 201TACE is the treatment most frequently adopted, alone or in
combination with ablation/resection, in patients listed for LT
(bridging treatments) [3,27–42], or included in a program of
downstaging [3,29,34,37,40–48]. Results of neo-adjuvant locore-
gional treatments are reported as related to the use of TACE alone
[3,27,29,31,33,34,37,43,44,48], ablation alone [4,49,50], or multi-
modal treatments [28,30,32,35,36,38–42,45–47].
In general, most published series are single-center and with a
low number of patients. Furthermore, there is a great heterogene-
ity among studies as regards the types of treatments considered,
the center-speciﬁc criteria for LT for HCC, and the results reported
in terms of: achievement of tumor necrosis, radiological response
to treatment, dropout rate, waiting time for LT, proportion of
patients transplanted, post-transplant survival, intention-to-treat
survival and post-LT recurrence rate [3,4,27–51].
The highest accordance between different studies is in the
demonstration that RFA achieves higher rates of complete necro-
sis (46–74%) [4,49,50] compared with TACE (22–29%)
[27,35,48,51]. Cucchetti and colleagues showed that patients
treated with potentially curative bridge treatments, namely
resection and percutaneous ablation, had higher probabilities of
achieving a complete tumor response compared to those treated
with TACE [41], whereas Huo and colleagues reported a lower
incidence of dropout among patients treated with RFA vs. other
ablation procedures [36].
However, other outcome measures between different treat-
ments are highly variable, and a clear superiority of ablation
vs. TACE has not emerged so far. Considering all the above stud-
ies reporting results of either bridge or downstaging strategies,
the WL dropout rate ranges between 0% and 35%, the tumor pro-
gression rate ranges between 0% and 20%, the average waiting
time to LT is between 4 and 12 months, the proportion of
patients transplanted is between 54% and 100%, the post-LT
patient survival is between 76% at 3 years and 94% at 5 years,
and the intention-to-treat survival is between 57% and 94%
[3,4,28–42,49,50].
These ﬁgures have to be compared with initial studies report-
ing an actuarial probability of dropout of 15–30% at 1 year [9,52],
and with an analysis based on Organ Procurement and Transplant
Network data for WL registrations for HCC between 2005 and
2008, showing that the use of any type of ablation had a minimal
effect onWL dropout, which decreased from 10.1% for no ablation
to 8.0% for ablation at 180 days after listing [53].
The effect of neo-adjuvant treatments on survival after LT is
even more difﬁcult to assess. Many studies indicate survival rates
similar to those of untreated individuals [27,35,51,54,55], but
data from the U.S. activity of liver transplant for HCC from
1997 to 2006 showed a higher 3-year post-LT survival in patients
who received pre-LT ablative procedures compared to those who
did not, without any apparent difference among different types of
pre-LT treatments [56].
In general, studies reporting no differences between treated
and untreated patients tend to have shorter waiting times
(<6 months) for LT [35,51], as clearly exempliﬁed by a national
survey of LT for HCC from 1998 to 2006 by Pellettier et al., where
the median waiting time to LT was 2 months [54].
This explains once again the low level of recommendation
pertaining to neo-adjuvant treatments given during the Zurich
conference, which is mostly based on a Markov-based cost-effec-
tiveness analysis outlining the beneﬁts for neo-adjuvant treat-
ments when waiting times exceed 6 months [10,11].3 vol. 58 j 609–618 611
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Which are the patient or tumor characteristics related to an
unsuccessful neo-adjuvant therapy, a higher dropout rate, and
a worse post-LT outcome?
Table 1 depicts the numerically most relevant single-center ser-
ies reporting both neo-adjuvant treatments used and factors
affecting at least one of the main outcome measures before or
after LT (response to neo-adjuvant treatment, dropout rate from
the waiting list, post-transplant survival, HCC recurrence, and
intention-to-treat survival). Different types of therapies were
used, and untreated patients were considered in some studies
[28,30,35,38–42]. Also, in some papers, a proportion of patients
were treated with an intent of downstaging to eligibility criteria
for LT, but most authors did not state which further criteria for
downstaging were used at the initiation of the study, with only
two exceptions [40,41].
As reported above, these studies showed highly variable
methods and results, which are extensively described in previous
reviews [13,57–59]. However, under the present need to clearly
deﬁne the priority to be assigned to different stages of the disease
for better balancing with other indications for LT, the most
important objective is to evaluate the impact of neo-adjuvant
treatments among variables affecting 5 speciﬁc outcomes:
response to neo-adjuvant treatments, dropout rates from the
WL, patient survival after LT, HCC recurrence after LT, and inten-
tion-to-treat survival after listing. Very few studies addressed all
these issues, while most of them focused on only one or 2 out-
come measures. The assessment of response to neo-adjuvant
treatments was not performed with uniform criteria, which var-
iably included radiological complete response vs. partial or
absent response, radiological complete or partial response vs.
no response, or pathological response (necrosis) alone. In addi-
tion, most authors did not perform univariate and multivariate
analysis of all possible predictive factors. Indeed, only 2 recent
studies consistently adopted this methodology [40,41].
In general, tumor dimensional and biological characteristics
(more advanced tumor stage, HCC outside MC or subjected to
downstaging, and elevated serum AFP) had a negative impact
on the response to neo-adjuvant treatments [4,37,39–41,49,50].
These factors, together with no response to neo-adjuvant treat-
ments, absence of neo-adjuvant treatments, and poor liver func-
tion (expressed with Model for End-stage Liver Disease [MELD]
score, ascites or serum bilirubin), conditioned the probability of
dropout [3,30,32,36,39–41]. Interestingly, downstaging nega-
tively affected these outcomes in more than one reported study,
and it was also a negative predictor of post-LT survival, HCC
recurrence and intention-to-treat survival according to some
authors [3,29].
Finally, tumor recurrence and patient survival rates were
partly determined by the same factors conditioning pre-LT out-
comes (including response to neo-adjuvant treatments), and
partly affected by the aggressive tumor behavior, expressed by
vascular invasion and poor differentiation [3,28,29,34,35,38,40–
42]. Hepatitis C virus (HCV) recurrence was an independent pre-
dictor of lower patient survival in one study [41] (Table 1).
Results of studies speciﬁcally addressing downstaging
Several authors speciﬁcally focused on the results of downstaging
protocols [29,34,37,43–48]. Even in these studies, a high variabil-
ity of methods and results is evident. Successful downstaging was612 Journal of Hepatology 201deﬁned as fulﬁlling of MC [37,44,47,48], UCSF criteria [45], MC
with simultaneous drop of serum AFP below 400 ng/ml [46], or
30–50% decrease in size of HCC nodule(s) [29,34].
Treatments used for downstaging included a higher preva-
lence of TACE alone [29,34,43,44,48], with a few studies reporting
multimodal procedures [45–47] or transarterial chemoinfusion
[37]. Only 2 prospective studies established a priori upper numer-
ical and dimensional limits of HCC, before entering the downstag-
ing protocol [45,46].
The average number of neo-adjuvant treatments ranges
between 1 and 5, the successful downstaging rate ranges
between 24% and 75%, the proportion of patients transplanted
ranges between 10% and 67%, the average waiting time to LT
ranges between 2 and 10.9 months, the post-LT patient survival
rate ranges between 41% at 4 years and 93.8% at 5 years, the
recurrence-free survival rate ranges between 40% at 5 years and
92% at 2 years (with 4 studies having a 63 year survival esti-
mate), and intention-to-treat survival ranges between 19% and
84% at 3 years (with 3 studies not reporting intention-to-treat
survival) [29,34,37,43–48,57–59].
During the Zurich conference, these initial and varying results
of downstaging formed the basis upon which LT was strongly
indicated if the expected 5-year survival is comparable to that
of HCC patients who meet the criteria for LT without requiring
downstaging, while no recommendation could be made for pre-
ferring a speciﬁc locoregional therapy for downstaging [10].Can the effect of neo-adjuvant treatments be used to balance
priority of HCC and non-HCC candidates?
One important aspect related to locoregional treatments in
potential candidates to LT is the deﬁnition of how the response
to bridge therapies might impact on WL priority, especially vs.
non-HCC patients, in an era of persistent scarcity of organ donors.
Allocation rules for patients with HCC, waiting for LT under
the MELD-based policy, are still a difﬁcult issue in continuous
evolution. Since March 2005, the UNOS policy states that patients
with a T1-HCC do not receive extra MELD points whereas a MELD
score of 22 is given to patients with a T2-HCC [60,61].
The UNOS priority for HCC patients was based on the replace-
ment of the native MELD score, assessing the risk of death due to
liver failure, by an estimation of the risk of tumoral progression.
However, HCC patients appear to be advantaged in the current
system, the role of bridge therapies in modifying both dropout
rates due to tumor progression and priority policy still needs to
be clariﬁed, and the question is raised as to whether added prior-
ity is necessary [62].
In fact, the current HCC policy does not seem to adhere to the
general principles for liver allocation adopted with the introduc-
tion of the MELD score: HCC patients still have better access to
the liver transplant donor pool compared with non-HCC patients
and local WL HCC treatments are not taken into account [62,63].
For these reasons, the development of a more dynamic score has
been highly endorsed, including the role of bridge therapies [63].
Three studies reported in Table 1 appear to address these
issues [39–41]. A ﬁrst report from De Giorgio and colleagues in
2010 suggested that response to bridge therapies can predict
tumor progression beyond the MC, and should be taken into
account in models designed to prioritize organ allocation. The
authors applied a center-speciﬁc allocation policy for 206 HCC3 vol. 58 j 609–618
Table 1. Numerically most relevant single-center series reporting both neo-adjuvant treatments used and factors affecting at least one of the main outcome measures
before or after LT (response to neo-adjuvant treatment, dropout rate from the waiting list, post-transplant survival, HCC recurrence, and intention-to-treat survival).
Author 
[Ref.]
NAT Bridging 
(No. of patients)
Downstaging 
(No. of patients) 
Indicators of a worse outcome
No response 
to NAT
Dropout from WL Survival after LT HCC recurrence 
after LT
ITT survival
Herrero, 
2001 [28]
TACE, RFA, 
PEI, none
Bridging (47) n.a. n.a. Stage IV HCC Stage IV HCC n.a.
Graziadei, 
2003 [29]
TACE Bridging (48)
Downstaging* (15)
n.a. n.a. Downstaging n.a. Downstaging
Yao, 
2003 [30]
TACE, RFA, 
PEI, resection, 
none
Bridging (70) n.a. ≥3 nodules, 
1 nodule >3 cm
No NAT
n.a. n.a. n.a.
Hayashi, 
2004 [31]
TACE Bridging (20) n.a. None None None n.a.
Fisher, 
2004 [32]
TACE, TACI, 
RFA, PEI
Bridging (33) n.a. AFP >400 ng/ml
T3 tumor stage
Bilobar HCC
n.a. n.a. n.a.
Maddala, 
2004 [33]
TACE Bridging (54) Multiple nodules None n.a. None n.a.
Mazzaferro, 
2004 [4]
RFA Bridging (50) Tumor size >3 cm n.a. n.a. n.a. n.a.
Lu,
2005 [49]
RFA Bridging (24) Tumor size >2.5 cm
Perivascular location
n.a. n.a. n.a. n.a.
Pompili, 
2006 [50]
RFA, PEI Bridging (40) Tumor size >3 cm n.a. n.a. n.a. n.a.
Otto, 
2006 [34]
TACE Bridging (34)
Downstaging* (62)
n.a. n.a. n.a. No response to NAT
Number of nodules
Poor differentiation
n.a.
Porrett, 
2006 [35]
TACE, RFA, 
PEI, TARE, 
none
Bridging (64) None n.a. No response to NAT None n.a.
Millonig, 
2007 [3]
TACE Bridging (101)
Downstaging* (15)
n.a. No response to NAT 
Downstaging
No response to NAT
Downstaging
AFP** >11 ng/ml
Out MC 
Downstaging
No response 
to NAT
Downstaging
AFP** >11 
ng/ml
Huo, 
2008 [36]
TACE, RFA, 
PAI, PEI
Bridging (390) n.a. NAT not including 
RFA
Tumor stage
n.a. n.a. n.a.
De Luna, 
2009 [37]
TACI Bridging (95)
Downstaging* (27)
Out MC Older age None None None
Vibert, 
2010^ [38]
TACE, RFA, 
cryoablation, 
resection, none
Bridging (153)
Downstaging* 
(not specified)
n.a. n.a. ≥3 nodules
AFP progression 
>15 ng/ml/month
Age >60 yr
≥3 nodules
Out MC
AFP progression 
>15 ng/ml/month
n.a.
De Giorgio, 
2010§ [39]
TACE, RFA, 
PEI, resection, 
none
Bridging (170) Tumor stage Ascites
Total tumor 
diameter
No response to NAT 
n.a. n.a. n.a.
Vitale, 
2010§§ [40]
TACE, RFA, 
PEI, resection, 
none
Bridging (110)
Downstaging* (37)
No HCV infection
Elevated AFP
Tumor size
Tumor stage
No NAT
No response to NAT
Elevated bilirubin
None No response to NAT
Tumor size
Tumor number
Out MC
MVI
Poor differentiation
No response 
to NAT
Cucchetti, 
2011 [41]
TACE, RFA, 
PEI, resection, 
none
Bridging (262)
Downstaging (53)
TACE vs. others
Multiple nodules
AFP** >400 ng/ml
Downstaging
MELD score
Tumor stage
No NAT
No response to NAT
HCV infection
MVI
No response to NAT
MVI
No response 
to NAT
Ciccarelli, 
2012 [42]
TACE, RFA, 
PEI, resection, 
none
Bridging (120)
Downstaging* (17)
n.a. n.a. n.a. Tumor number >3
AFP** ≥400 ng/ml
No NAT
MVI
ALA for rejection
n.a.
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HCC, hepatocellular carcinoma; NAT, neo-adjuvant treatments; WL, waiting list; LT, liver transplantation; ITT, intention-to-treat; TACE, transarterial chemoembolization;
RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; n.a., not assessed; TACI, transarterial chemoinfusion; AFP, alpha-fetoprotein; TARE, transarterial
radioembolization; MC, Milan criteria; PAI, percutaneous acetic acid injection; HCV, hepatitis C virus; MVI, microvascular invasion; ALA, antilymphocytic antibodies.
⁄In these studies, the inclusion criterion for downstaging was simply deﬁned as HCC initially outside MC or University of San Francisco Criteria, without further
speciﬁcation, except the study by Vitale et al. [40], in which poor tumor differentiation detected by pre-LT biopsy was an additional exclusion criterion.
⁄⁄In these studies, AFP at the moment of diagnosis of HCC was considered.
^In this study, only AFP-secreting HCCs were considered, patients dropped out were excluded, and factors related to recurrence-free survival instead of HCC recurrence were
investigated.
§In this study, the time to progression beyond the MC or death was considered instead of the dropout rate.
§§In this study, dropout criteria included poorly differentiated HCC at pre-LT biopsy.
Frontiers in Liver Transplantationcandidates (T1: 31 patients, T2: 175 patients) and compared their
observed progression rate beyond MC with the expected rate
applying the UNOS risk estimation. In the De Giorgio experience,
percutaneous ablation represented the most frequent strategy
adopted (62.8%), followed by hepatic resection (20.7%) and TACE
(14.6%). Total tumor diameter and recurrence/persistence of
tumor activity at the 6-week control after bridge therapy were
the tumor factors that signiﬁcantly correlated with dropout from
the WL; unfortunately, no criteria for deﬁnition of recurrence/
persistence were provided, nor were characteristics of patients
in relationship to response to treatment. However, the
authors reported an interesting analysis showing that the current
UNOS allocation policy largely overestimates the risk of tumor
progression. They also suggested a modiﬁed allocation policy in
which T2-HCC patients received their natural MELD scores at the
time of diagnosis with 3-point increment in the MELD score at
3-month intervals and receiving 22-point MELD exception only
at the time of recurrence/persistence after bridge therapies. Even
if no data were provided about the ability of different bridge
approaches in obtaining tumor response, taken together, these
results support a potential role of bridge therapy in reducing the
dropout risk and in determining allocation priority. Finally, it
should be noted that no data were provided about the post-
transplant course in relationship to response to bridge therapy
[39].
Some answers raised by the De Giorgio study can be found in
another report published by Vitale and colleagues in the same
year [40]. In a population of 147 HCC candidates (38% outside
Milan criteria), a complete or partial response to bridge therapies
was observed in 57.8% (using RECIST criteria) of cases. Multi-
modal treatment was adopted in 24% of cases, and no signiﬁcant
difference was observed between percutaneous ablation and
TACE modalities in relationship with tumor response. In particu-
lar, RFA was adopted in 64.7% of cases with complete/partial
response and in 61.3% of cases with stable/progressive disease;
TACE was adopted in 22% of cases with complete/partial response
and in 11% of cases with stable/progressive disease (p = 0.068).
Thus, no suggestions can be obtained about the optimal bridge
therapy to be adopted, but the authors showed, in a competing-
risk analysis, that the dropout probability of patients achieving
complete or partial response was signiﬁcantly lower than that
of their counterpart. The authors suggested, and applied, a prior-
ity score to patients with stable/progressive disease. However,
prioritizing patients not responding to bridge therapies may
select lesions at a higher risk for recurrence after transplantation
[64]. Even if Vitale and colleagues showed that patient survival
was substantially unaffected, with a 3-year post-LT survival of
83% in patients with complete/partial response and 82% in
patients with stable/progressive disease, they obtained a 6-fold
increase in tumor recurrence after transplantation in the latter
group (from 2% to 13%; p = 0.04). Bridge therapy could reduce
the dropout risk of HCC candidates, but if a prioritization of614 Journal of Hepatology 201non-responder patients is accepted, a worsening in the post-
operative outcome could be expected [40].
The ﬁndings of the Vitale report were made more robust by a
retrospective study by Cucchetti and colleagues in 2011 [41],
designed to assess the effectiveness of bridge therapy in prevent-
ing removal from the WL for tumor progression beyond the MC
and in determining post-transplant outcomes. The study was
conducted on data from 315 candidates, and competing-risk
analysis was applied to control for transplant event.
At the 3-month control after the ﬁrst bridge procedure, a com-
plete response (assessed with mRECIST criteria) was observed in
49.1% of candidates. These patients showed a signiﬁcant reduc-
tion in the dropout probability at 3, 6, and 12 months after treat-
ment. The dropout probability was signiﬁcantly affected by the
MELD score, the tumor stage at diagnosis, and the response to
bridge therapy.
The dropout risk for patients with T1 tumors was very similar
to the risk observed for patients with T2 tumors and a complete
response to bridge therapy (p = 0.964). Conversely, the dropout
risk for patients with T2 tumors and a partial response or no
response to bridge therapy was signiﬁcantly higher than the risk
for both T1 patients (p = 0.001) and T2 patients with a complete
response (p = 0.001). The dropout risk for patients who were sub-
jected to a downstaging procedure (T3–T4a patients) was signif-
icantly higher than the risk for all T1 patients and T2 patients
with a complete response (p = 0.024) and was lower than the risk
for T2 patients with a partial response or no response to bridge
therapy (p = 0.037). The dropout risk of HCC patients with respect
to the TNM stage, the response to bridge therapy, and the down-
staging procedure is depicted in Fig. 1.
On the basis of these observations, the authors suggested that
the priority of T2-HCC candidates can be reduced after successful
bridge therapy, supporting the ﬁndings of De Giorgio and col-
leagues. Excluding hepatic resection that was related to a 4-fold
increased probability of complete tumor response, TACE was
the most frequent therapeutic strategy adopted (53.9%); percuta-
neous ablation (RFA or PEI), in combination or not with TACE,
represented 26.0% of treatments. TACE was adopted in 49.3% of
cases with complete response and in 57.9% of cases with partial
or no response (p = 0.177); percutaneous ablation was adopted
in 29.2% of cases with complete response and in 23.4% of cases
with partial or no response (p = 0.032). Thus, differently from
what was reported by Vitale et al. [40], patients treated with
potentially curative bridge treatments, namely resection and per-
cutaneous ablation, showed higher probabilities of achieving a
complete tumor response. Other factors determining a lower
probability of obtaining a complete response after treatment
were AFP >400 ng/ml at diagnosis, multiple nodules of HCC,
and inclusion in a downstaging protocol.
Focusing the analysis on transplanted patients, the authors
found that patients with partial or no response to bridge thera-
pies experienced a signiﬁcantly higher recurrence-rate after3 vol. 58 j 609–618
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Fig. 1. Competing risk analysis of dropout from the waiting list depending on
TNM stage, downstaging procedure, and response to neo-adjuvant therapy.
(A) T1 patients and T2 patients with a complete response to neo-adjuvant
treatments had similar dropout risks, which were lower than the risk observed for
T2 patients with a partial response or no response. (B) T1 patients and T2 patients
with a complete response had a dropout risk lower than that observed for
patients subjected to downstaging, whose risk was in turn lower than that
observed for T2 patients with a partial response or no response. (C) The dropout
risk due to tumor progression is shown according to tumor stages and responses
to treatments (p = 0.001). (Cucchetti et al. [41] reprinted with permission).
JOURNAL OF HEPATOLOGYtransplant (5-year recurrence rate = 19.4% vs. 5.5% of the counter-
part). The second factor affecting a lower recurrence-free survival
was the presence of tumor microvascular invasion.
Patients with partial or no response to neo-adjuvant treat-
ments had a non-signiﬁcantly lower patient survival (p = 0.098),
which was mainly inﬂuenced by HCV positivity and presence of
microvascular invasion at histology. Conversely to what was con-
cluded by Vitale in 2010, response to treatment was not sug-
gested as a tool to give further priority to HCC patients, but to
reduce it in selected T2-HCC patients. Concerning HCV–HCC
patients, one consequence of this policy is that when a complete
viral and tumor response is obtained after treatment, their prob-
ability of being transplanted becomes so low that they could be
maintained inactive in the WL, with LT as an option in the case
of future recurrent disease.
In general, and while waiting for more accurate molecular
markers, the response to pre-LT treatments could represent a sur-Journal of Hepatology 201rogate but extremely practical marker of tumor biology and could
be helpful in the selection of candidates for LT. Especially in the
case of patients with aggressive HCC (i.e., those at the upper limit
of MC or UCSF criteria, or those with high or increasing levels of
AFP), the test of time (3 months of observation after a locore-
gional treatment and subsequent re-staging) would be helpful
in selecting HCC candidates at acceptable risk of HCC recurrence
after LT. Importantly, this ‘‘ablate and wait’’ strategy [65] appears
to be a valid approach also for balancing the priority to HCC or
non-HCC patients on the waiting list.
Depending on the waiting time and the characteristics of the
population on the list, each institution must calculate the most
equitable policy for its patients. Periodical reassessment of the
policy is also recommendable to avoid imbalance among
candidates.
A continuous score incorporating MELD, AFP and tumor size
may help prioritize HCC patients to better equate dropout rates
with non-HCC patients and equalize access according to the
above mentioned study by Washburn et al. [53,62].
In a very recent study based on the Scientiﬁc Registry of
Transplant Recipients and including almost 50,000 adult candi-
dates for LT, Toso et al. [66] demonstrated that the risk of dropout
of HCC patients was independently predicted by MELD score, HCC
size, HCC number, and AFP. They applied a proportional hazard
competitive risk model, and by combining patient age and diag-
nosis, these factors allowed for the extrapolation of the risk of
dropout. Since this model and MELD did not share compatible
scales, a correlation between both models was computed accord-
ing to the predicted risk of dropout, and dropout equivalent
MELD (deMELD) points were calculated. The new and very com-
plex formula is as follows:
deMELD ¼ 25þ 0:1  Ageþ 1:6 MELD
þ 1:6  TumorSizeþ 1:3  LogAFP
þ 6:0 if Nb TumorsP 2
þ 0 if Diag ¼ HCV
 1 if Diag ¼ HBC
þ 3 if Diag ¼ Alcohol
þ 3 if Diag ¼ NASH
þ 1 if Diag ¼ Hemoc
þ 1 if Diag ¼ Other:
The use of continuous variables, the evaluation of HCC and
non-HCC patients with uniform criteria, and the ‘‘dynamic’’ con-
cept of the revised MELD are the major advancements related to
this equation. In particular, deMELD can be recalculated at any
time and has the ability to capture changes of the risk of dropout
from the WL, for example as a consequence of neo-adjuvant
treatments. In this perspective, lesions with complete radiologi-
cal response should not be counted as nodules, while those with
partial or absent response should be considered with their max-
imum baseline diameter.
By applying this formula, the authors demonstrated that the
current 22 points allocated to T2 patients in the US represent
too many exception points, so that 95.2% of T2 HCC patients
are unfairly advantaged as compared with the deMELD.Are there new molecular markers for a better estimation of
tumor biological behavior and/or response to treatment?
Serum markers such as AFP or protein induced by vitamin K
absence or antagonism factor II increase predictive accuracy if3 vol. 58 j 609–618 615
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used in addition to morphological features of HCC [46,67–69],
probably because they are reliable indicators of tumor biology,
including microvascular invasion and tumor grade.
New speciﬁc molecular signatures or markers in HCC or in the
adjacent hepatic tissue have been shown to correlate with out-
come and to predict the risk of tumor recurrence after treatment
[70]. Among these factors, epithelial cell adhesion molecule
(EpCAM) [71,72], the g3-proliferation subclass [73], the expres-
sion status of the miR-26 miRNA precursor [74], two gene prog-
nostic signature in non-tumor hepatic tissue [75,76], and
fractional allelic imbalance have been described [77]. These
molecular markers could be assessed in patients undergoing
locoregional treatments in order to predict the risk of dropout
and tumor recurrence after LT [18]. However, they require exter-
nal validation before they can be used in the clinical practice.
Conclusions
According to the present evidence, the following concepts should
be applied for the use of neo-adjuvant treatments in candidates
for LT for HCC:
(1) A recent consensus conference established that neo-adjuvant
treatments are indicated in patients considered for LT if the
waiting time for LT is expected to be longer than 6 months.
However, the widespread policy of treating most patients
in the WL, especially those at risk of tumor progression,
seems justiﬁed given the often unpredictable waiting time
for LT and the opportunity to use the response to therapy
as a prioritization parameter (see also conclusion 4).
(2) The response to treatments should be evaluated with mRE-
CIST criteria and through a 3-month periodical reassess-
ment, including radiological imaging and serum AFP
sampling.
(3) The type of locoregional treatment should include TACE
and standard ablation techniques (RFA, PEI), to be chosen
according to the BCLC scoring system; ablation techniques
can be applied laparoscopically, if permitted by the degree
of liver function; liver resection can be used as bridging or
downstaging procedure in BCLC 0-A stages in experienced
centers; other procedures (TACE-DEB, TARE, radiotherapy,
microwave ablation, cryoablation, and irreversible electro-
poration), though promising, should still be considered
under investigation.
(4) Neo-adjuvant treatments, especially if applied as multi-
modal approach, have the 3 main purposes of (A) effec-
tively controlling HCC for expected long waiting times;
(B) identifying patients with high or low probability of
cancer progression; (C) based on these risk categories,
helping in balancing the priority of HCC and non-HCC-can-
didates through revised additional scores for HCC.
(5) Due to the low number of prospective studies with well-
deﬁned entry criteria and the high variability of results,
the role of downstaging is still to be deﬁned with large,
multicenter trials.
(6) Although new molecular markers for a better estimation of
tumor biological behavior and/or response to treatment
have been investigated with promising results, at present,
they cannot be translated into a routine use in clinical
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